Compare Stocks: CRDF, FATE, RNAC, and IVVD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.08 +1.9%	$1.02	$0.76 ▼ $3.31	$82.46M	1.46	701,192 shs	374,459 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
IVVD Invivyd	$0.84 +3.9%	$0.78	$0.53 ▼ $3.07	$236.99M	0.81	4.25 million shs	2.58 million shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+1.89%	+9.52%	+16.27%	-28.00%	-44.90%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
IVVD Invivyd	+3.86%	-7.23%	+45.67%	-18.93%	-19.71%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.08 +1.9%	$1.02	$0.76 ▼ $3.31	$82.46M	1.46	701,192 shs	374,459 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
IVVD Invivyd	$0.84 +3.9%	$0.78	$0.53 ▼ $3.07	$236.99M	0.81	4.25 million shs	2.58 million shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+1.89%	+9.52%	+16.27%	-28.00%	-44.90%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
IVVD Invivyd	+3.86%	-7.23%	+45.67%	-18.93%	-19.71%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.14	Hold	$7.50	594.44% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	143.80% Upside
IVVD Invivyd	2.33	Hold	$8.00	858.08% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	257.46% Upside

Current Analyst Ratings Breakdown

Latest CRDF, FATE, RNAC, and IVVD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/11/2026	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$590K	142.40	N/A	N/A	$0.34 per share	3.18
FATE Fate Therapeutics	$6.65M	43.60	N/A	N/A	$1.28 per share	1.89
IVVD Invivyd	$53.43M	4.61	N/A	N/A	$0.61 per share	1.37
RNAC Cartesian Therapeutics	$2.80M	98.53	N/A	N/A	($4.14) per share	-2.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.85M	-$0.60	N/A	N/A	N/A	-7,885.43%	-103.10%	-75.52%	11/5/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)

Latest CRDF, FATE, RNAC, and IVVD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/11/2026	Q2 2026	CRDF Cardiff Oncology	-$0.1196	-$0.14	-$0.0204	-$0.14	$0.06 million	$0.10 million
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	3.30	3.30
FATE Fate Therapeutics	N/A	4.85	4.85
IVVD Invivyd	N/A	5.87	5.87
RNAC Cartesian Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FATE Fate Therapeutics	97.54%
IVVD Invivyd	70.36%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	8.80%
FATE Fate Therapeutics	4.74%
IVVD Invivyd	12.25%
RNAC Cartesian Therapeutics	37.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	77.79 million	70.95 million	Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
IVVD Invivyd	100	294.76 million	258.65 million	Optionable
RNAC Cartesian Therapeutics	64	30.25 million	19.00 million	Optionable

CRDF, FATE, RNAC, and IVVD Headlines

Recent News About These Companies

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

September 3 at 7:00 AM | globenewswire.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $32.60 Consensus Target Price from Brokerages

August 29, 2026 | americanbankingnews.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Brokerages

August 24, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)

August 18, 2026 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for RNAC

August 11, 2026 | marketbeat.com

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

August 9, 2026 | theglobeandmail.com

Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results

August 8, 2026 | marketbeat.com

Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | marketbeat.com

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2026 | globenewswire.com

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

August 6, 2026 | quiverquant.comQ

Cartesian Therapeutics Inc RNAC

July 12, 2026 | morningstar.comM

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

July 2, 2026 | theglobeandmail.com

Cartesian Therapeutics Announces New Employment Inducement Grants

July 2, 2026 | globenewswire.com

New Strong Sell Stocks for July 1st

July 1, 2026 | zacks.com

Cartesian Therapeutics Shareholders Back Directors and Governance Measures

June 17, 2026 | tipranks.com

Cartesian Therapeutics Announces New Employment Inducement Grant

June 12, 2026 | globenewswire.com

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 12, 2026 | theglobeandmail.com

Cartesian climbs on licensing deal with WestGene for CAR-T therapies

June 9, 2026 | seekingalpha.com

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

June 9, 2026 | globenewswire.com

Cartesian Therapeutics (RNAC) Gets a Buy from Wedbush

May 29, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, FATE, RNAC, and IVVD Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$1.08 +0.02 (+1.89%)

As of 09/3/2026 04:00 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Fate Therapeutics NASDAQ:FATE

$2.42 -0.03 (-1.22%)

As of 09/3/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Invivyd NASDAQ:IVVD

$0.84 +0.03 (+3.86%)

As of 09/3/2026 04:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$9.12 +0.04 (+0.44%)

As of 09/3/2026 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDF, FATE, RNAC, and IVVD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDF, FATE, RNAC, and IVVD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDF, FATE, RNAC, and IVVD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, FATE, RNAC, and IVVD Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Fate Therapeutics NASDAQ:FATE

Invivyd NASDAQ:IVVD

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRDF, FATE, RNAC, and IVVD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRDF, FATE, RNAC, and IVVD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRDF, FATE, RNAC, and IVVD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDF, FATE, RNAC, and IVVD Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Fate Therapeutics NASDAQ:FATE

Invivyd NASDAQ:IVVD

Cartesian Therapeutics NASDAQ:RNAC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools